Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 4/20 | 0.44 |
| ▸ | ADH1A | P07327 | 4/20 | 0.44 |
| ▸ | ADH1C | P00326 | 3/20 | 0.41 |
| ▸ | ADH7 | P40394 | 2/20 | 0.41 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23573431 | 0.83 | ATM (0.36) | POLB | |
| SCHEMBL23573316 | 0.82 | ADH1B (0.64) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL21319727 | 0.80 | ADH1B (0.65) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL23573330 | 0.77 | ADH1B (0.39) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL19972633 | 0.74 | POLB (0.31) | POLB | |
| SCHEMBL23524585 | 0.74 | POLB (0.31) | POLB | |
| SCHEMBL5007222 | 0.72 | POLB (0.41) | POLB | |
| SCHEMBL15970550 | 0.72 | POLB (0.41) | POLB | |
| SCHEMBL15204515 | 0.71 | ATM (0.30) | — | |
| SCHEMBL22233265 | 0.71 | GABRR1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ADORA2A, ENTPD1 | ADH1B 104/4885ADH1A 591/4885ADH1C 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.